New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
07:39 EDTCVS, CAHCardinal Health sees CVS Caremark venture operational as soon as July 1
In December 2013, Cardinal Health (CAH) and CVS Caremark (CVS) announced the signing of an agreement to form the largest generic sourcing entity in the U.S. Both companies are contributing their sourcing and supply chain expertise to the 50/50 joint venture and are committing to source generic drugs through it. The U.S.-based joint venture is expected to be operational as soon as July 1 and will have an initial term of 10 years, Cardinal said.
News For CAH;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
07:08 EDTCAHHenry Schein, Cardinal Health Enter long-term strategic agreement
Cardinal Health (CAH) and Henry Schein (HSIC) announced that the companies have entered into a long-term strategic agreement to provide one of the most comprehensive service and product offerings to office-based medical practices. This strategic agreement combines Cardinal Health's product line and extensive touch points across the health system with Henry Schein's outstanding service capabilities and history in serving office-based practices. Under the terms of the agreement, the physician office-focused commercial organization of Cardinal Health's Medical segment will be consolidated into the commercial organization of Henry Schein's Medical Group. Henry Schein has committed to purchase Cardinal Health Brand products and utilize Cardinal Health as a primary source for various medical products.
November 17, 2014
08:37 EDTCAHCardinal Health management to meet with FBR Capital
Meetings to be held in the Midwest November 17-18 hosted by FBR Capital.
November 14, 2014
14:53 EDTCVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use